Молекулярный анализ химерного онкогена BCR/ABL при остром лимфобластном лейкозе в Узбекистане

Аннотация

Subject of research: 420 patients with acute leukemia. Purpose of work: to study genetic variants and the frequency of chimeric oncogene BCR/ABL and implement a differentiated protocol of diagnosis and treatment of Ph-positive acute lymphoblastic leukemia in Uzbekistan. Methods of research: Clinical, morphological, molecular genetics, statistics. The results obtained and their novelty: Genetic marker's BCR/ABL pl90 level rate has been presented first in Uzbekistan and it's level is presented 34%; p210 variant has not been presented. High percent level of relapses in acute lymphoblastic leukemia patients was determined in high risk group compared standard in retrospective analysis of standard schemas. Remission is achieved more than 8 times reliable frequently in BCR/ABL-positive acute lymphoblastic leukemia patients, who had been treated Glivec with chemotherapy simultaneously comparing patients without Glivec treatment (%2=7,2; p=0,003; OR=8,25). Practical value: molecular detection method of chimera oncogen BCR/ABL pl90 has been optimized and introduced. This created possibility to present differential diagnostic of acute ALL, estimate molecular response for treatment and control molecular recidivc development and resistance flow of disease Degree of embed and economic effectively: the results of this study were introduced into the clinic practice Institute of Hematology and blood transfusion, materials used in the loaming process in the Hematology Department of the Medical Academy of advanced studies. Field of application: Hematology.